BSC
CPRX icon

BOLTON SECURITIES CORPORATION’s Catalyst Pharmaceutical CPRX Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.8K Buy
+1,000
New +$23.8K ﹤0.01% 1405
2025
Q3 		$19.7K Buy
+1,000
New +$20.6K ﹤0.01% 1389
2025
Q1 		$36.4K Buy
+1,500
New +$33.8K ﹤0.01% 1126

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

BOLTON SECURITIES CORPORATION's CPRX Position: Q1 2026 in Review

BOLTON SECURITIES CORPORATION opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 1,000 shares worth $24.8K. The stake represents ﹤0.01% of the portfolio and ranks #1405 among its holdings. This is a return to the name: BOLTON SECURITIES CORPORATION previously reported a position in CPRX as recently as Q3 2025.

BOLTON SECURITIES CORPORATION first reported a position in CPRX in Q1 2025 and has held it in 3 quarters since. The position peaked at $36.4K in Q1 2025. 387 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • BOLTON SECURITIES CORPORATION held 1,000 shares of Catalyst Pharmaceutical worth $24.8K as of Q1 2026.
  • Catalyst Pharmaceutical was a new BOLTON SECURITIES CORPORATION position in Q1 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of BOLTON SECURITIES CORPORATION's portfolio in Q1 2026, its #1405 holding.
  • BOLTON SECURITIES CORPORATION first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 3 quarters since.
  • BOLTON SECURITIES CORPORATION's Catalyst Pharmaceutical position peaked at $36.4K in Q1 2025.
  • 387 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q1 2026, filed 12 Nov 2026.